Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.13
AUXL's Cash to Debt is ranked lower than
91% of the 702 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.66 vs. AUXL: 0.13 )
Ranked among companies with meaningful Cash to Debt only.
AUXL' s 10-Year Cash to Debt Range
Min: 0.08  Med: 10000.00 Max: 15218
Current: 0.13
0.08
15218
Equity to Asset 0.14
AUXL's Equity to Asset is ranked lower than
95% of the 563 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. AUXL: 0.14 )
Ranked among companies with meaningful Equity to Asset only.
AUXL' s 10-Year Equity to Asset Range
Min: -2.27  Med: 0.41 Max: 0.68
Current: 0.14
-2.27
0.68
F-Score: 2
Z-Score: 0.59
M-Score: -2.95
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -27.33
AUXL's Operating margin (%) is ranked lower than
86% of the 660 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.81 vs. AUXL: -27.33 )
Ranked among companies with meaningful Operating margin (%) only.
AUXL' s 10-Year Operating margin (%) Range
Min: -335.41  Med: -38.35 Max: 21.62
Current: -27.33
-335.41
21.62
Net-margin (%) -36.62
AUXL's Net-margin (%) is ranked lower than
87% of the 661 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.92 vs. AUXL: -36.62 )
Ranked among companies with meaningful Net-margin (%) only.
AUXL' s 10-Year Net-margin (%) Range
Min: -327.31  Med: -36.92 Max: 21.74
Current: -36.62
-327.31
21.74
ROE (%) -68.63
AUXL's ROE (%) is ranked lower than
91% of the 685 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.31 vs. AUXL: -68.63 )
Ranked among companies with meaningful ROE (%) only.
AUXL' s 10-Year ROE (%) Range
Min: -111.79  Med: -68.63 Max: 60.46
Current: -68.63
-111.79
60.46
ROA (%) -12.88
AUXL's ROA (%) is ranked lower than
81% of the 706 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.19 vs. AUXL: -12.88 )
Ranked among companies with meaningful ROA (%) only.
AUXL' s 10-Year ROA (%) Range
Min: -1000.92  Med: -44.31 Max: 27.33
Current: -12.88
-1000.92
27.33
ROC (Joel Greenblatt) (%) -313.48
AUXL's ROC (Joel Greenblatt) (%) is ranked lower than
88% of the 704 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.13 vs. AUXL: -313.48 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AUXL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2174.84  Med: -445.93 Max: 290.53
Current: -313.48
-2174.84
290.53
Revenue Growth (3Y)(%) 22.10
AUXL's Revenue Growth (3Y)(%) is ranked higher than
84% of the 540 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. AUXL: 22.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AUXL' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 19.40 Max: 28.7
Current: 22.1
0
28.7
EBITDA Growth (3Y)(%) -36.80
AUXL's EBITDA Growth (3Y)(%) is ranked lower than
92% of the 483 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.80 vs. AUXL: -36.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
AUXL' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -68.8  Med: -24.60 Max: 75
Current: -36.8
-68.8
75
EPS Growth (3Y)(%) -30.00
AUXL's EPS Growth (3Y)(%) is ranked lower than
83% of the 452 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.20 vs. AUXL: -30.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
AUXL' s 10-Year EPS Growth (3Y)(%) Range
Min: -70.7  Med: -22.40 Max: 81.6
Current: -30
-70.7
81.6
» AUXL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

AUXL Guru Trades in Q2 2014

Louis Moore Bacon 150,000 sh (New)
John Paulson 4,000,000 sh (unchged)
Paul Tudor Jones Sold Out
Jim Simons Sold Out
» More
Q3 2014

AUXL Guru Trades in Q3 2014

Mario Gabelli 10,900 sh (New)
John Paulson 4,000,000 sh (unchged)
Louis Moore Bacon 100,000 sh (-33.33%)
» More
Q4 2014

AUXL Guru Trades in Q4 2014

Jeremy Grantham 1,281,312 sh (New)
Jim Simons 468,040 sh (New)
Mario Gabelli 35,885 sh (+229.22%)
Louis Moore Bacon Sold Out
John Paulson Sold Out
» More
Q1 2015

AUXL Guru Trades in Q1 2015

Jim Simons Sold Out
Jeremy Grantham Sold Out
Mario Gabelli Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with AUXL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 10.44
AUXL's Forward P/E is ranked higher than
91% of the 232 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.27 vs. AUXL: 10.44 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 11.47
AUXL's P/B is ranked lower than
90% of the 665 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.42 vs. AUXL: 11.47 )
Ranked among companies with meaningful P/B only.
AUXL' s 10-Year P/B Range
Min: 1.85  Med: 10.43 Max: 67.57
Current: 11.47
1.85
67.57
P/S 4.47
AUXL's P/S is ranked lower than
60% of the 653 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.30 vs. AUXL: 4.47 )
Ranked among companies with meaningful P/S only.
AUXL' s 10-Year P/S Range
Min: 0.45  Med: 4.24 Max: 15.15
Current: 4.47
0.45
15.15
Current Ratio 1.26
AUXL's Current Ratio is ranked lower than
80% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.27 vs. AUXL: 1.26 )
Ranked among companies with meaningful Current Ratio only.
AUXL' s 10-Year Current Ratio Range
Min: 0.99  Med: 2.94 Max: 5.85
Current: 1.26
0.99
5.85
Quick Ratio 0.99
AUXL's Quick Ratio is ranked lower than
75% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.66 vs. AUXL: 0.99 )
Ranked among companies with meaningful Quick Ratio only.
AUXL' s 10-Year Quick Ratio Range
Min: 0.71  Med: 2.48 Max: 5.59
Current: 0.99
0.71
5.59
Days Inventory 162.63
AUXL's Days Inventory is ranked lower than
71% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 113.56 vs. AUXL: 162.63 )
Ranked among companies with meaningful Days Inventory only.
AUXL' s 10-Year Days Inventory Range
Min: 58.95  Med: 129.86 Max: 1913.26
Current: 162.63
58.95
1913.26
Days Sales Outstanding 73.47
AUXL's Days Sales Outstanding is ranked lower than
51% of the 594 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.45 vs. AUXL: 73.47 )
Ranked among companies with meaningful Days Sales Outstanding only.
AUXL' s 10-Year Days Sales Outstanding Range
Min: 41.05  Med: 53.14 Max: 87.86
Current: 73.47
41.05
87.86

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) (%) -4.90
AUXL's Earnings Yield (Greenblatt) (%) is ranked lower than
83% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. AUXL: -4.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AUXL' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -4.9  Med: 7.75 Max: 30.9
Current: -4.9
-4.9
30.9

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:FEJ.Germany,
Auxilium Pharmaceuticals, Inc., incorporated in the state of Delaware in July 1999. The Company is a specialty biopharmaceutical company which develops and markets products for specialist audiences. The Company now have a portfolio of 12 approved products, including one product with two indications. Among other products in the U.S., Auxilium markets Testim (testosterone gel) for the topical treatment of hypogonadism, TESTOPEL (testosterone pellets) a long-acting implantable testosterone replacement therapy ("TRT") product, STENDRA (avanafil), an oral erectile dysfunction ("ED") therapy, Edex (alprostadil for injection), an injectable treatment for ED, Osbon ErecAid, the leading vacuum device for aiding ED, XIAFLEX (collagenase clostridium histolyticum or "CCH") for the treatment of Peyronie's disease ("PD" or "Peyronie's") and XIAFLEX for the treatment of Dupuytren's contracture ("DC" or "Dupuytren's"). We also have programs in Phase 2 clinical development for the treatment of Frozen Shoulder syndrome and cellulite, Striant, a buccal TRT, XIAFLEX for the treatment of PD in men with a palpable plaque and a curvature deformity of thirty degrees or greater at the start of therapy which was launched in the U.S. in January 2014 and is the first and only FDA-approved non-surgical treatment for PD. Approximately 75% of the Company's product shipments are to only three wholesalers: Cardinal Health, Inc., McKesson Corporation and AmerisourceBergen Corporation. The Company faces competition from competitors in North America, Europe and elsewhere from pharmaceutical companies, specialty pharmaceutical companies and biotechnology firms, universities and other research institutions and government agencies that are developing and commercializing pharmaceutical products.
» More Articles for AUXL

Headlines

Articles On GuruFocus.com
Endo International Posts Upbeat Q1 Results May 13 2015 
Endo Pharmaceuticals Posts A Solid Q1 Earnings Report May 12 2015 
Endo International Shares Upbeat After Positive Q4 Earnings Report Mar 03 2015 
John Paulson's Stocks Trading for Less Than He Paid for Them Jun 02 2014 
Auxilium Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 01 2011 
Auxilium Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 08 2010 
Auxilium Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2010 
Auxilium Pharmaceuticals Inc. Reports Operating Results (10-Q) May 07 2010 
Auxilium Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 05 2009 
Auxilium Pharmaceuticals Inc. (AUXL) CFO James E Fickenscher sells 4,000 Shares Sep 16 2009 

More From Other Websites
Pozen to redomicile as it agrees to buy Tribute Pharmaceuticals Jun 08 2015
Pozen to redomicile as it agrees to buy Tribute Pharmaceuticals Jun 08 2015
Endo International (ENDP) Earnings Report: Q1 2015 Conference Call Transcript May 11 2015
Endo International Tops Profit Views May 11 2015
Endo (ENDP) Beats on Q1 Earnings, 2015 Guidance Updated - Tale of the Tape May 11 2015
13F Watch: In Defense of Active Share Feb 19 2015
Auxilium Announces Fundamental Change and Make-Whole Fundamental Change Relating to Outstanding... Feb 03 2015
AUXILIUM PHARMACEUTICALS INC Files SEC form 8-K/A, Entry into a Material Definitive Agreement,... Jan 30 2015
AUXILIUM PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jan 29 2015
Endo Completes Acquisition Of Auxilium Pharmaceuticals Jan 29 2015
AUXILIUM PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security... Jan 27 2015
Auxilium Announces Results from Special Meeting of Stockholders Jan 27 2015
Auxilium Announces Results from Special Meeting of Stockholders Jan 27 2015
Endo Prices $1.2B Senior Notes Offering for Auxilium Deal - Analyst Blog Jan 22 2015
Big payday looming for Auxilium executives Jan 22 2015
AUXILIUM PHARMACEUTICALS INC Files SEC form 8-K, Other Events Jan 21 2015
AUXILIUM PHARMACEUTICALS INC Files SEC form 8-K, Other Events Jan 16 2015
OncoMed Starts Expansion Stage Study for Solid Tumor Drug - Analyst Blog Jan 16 2015
BioCryst's BCX4161 Recommended for Orphan Drug in EU - Analyst Blog Jan 15 2015
Endo changing its management structure Jan 09 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK